Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Pfizer (PFE) is 5/10.
Pfizer delivered Q1 revenues of $14.5 billion, exceeding expectations with 2% operational growth, and adjusted EPS of $0.75. Excluding COVID products, the underlying business delivered approximately 7% operational growth. The Vyndamax patent settlement extended exclusivity, and oncology pipeline readouts were positive. R&D investment increased 11% to support the pipeline. Full-year 2026 guidance was reaffirmed at $59.5-62.5 billion revenue and $2.80-$3.00 adjusted EPS. LOE headwinds through 2028 preceded a growth inflection.
Scored from Pfizer’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $17.76B | +21.9% | $0.07 | +112.1% | 32.2% | 2.3% | $5.80B |
| FY2025 Q1 | $13.71B | -7.8% | $0.52 | -5.1% | 33.7% | 21.6% | $1.77B |
| FY2025 Q2 | $14.65B | +10.3% | $0.51 | — | 24.4% | 19.9% | $-1.20B |
| FY2025 Q3 | $16.65B | -5.9% | $0.62 | -20.9% | 21.3% | 21.3% | $4.00B |
| FY2025 Q4 | $17.56B | -1.2% | $-0.29 | -503.3% | 21.0% | -9.4% | $4.50B |
| FY2026 Q1 | $14.45B | +5.4% | $0.47 | -9.5% | 27.9% | 18.6% | $2.18B |
| FY2026 Q2 | $15.03B | +2.6% | $-0.04 | -108.5% | 31.3% | -1.6% | $302M |